9,254 Shares in AbbVie Inc. $ABBV Acquired by North Dallas Bank & Trust Co.

North Dallas Bank & Trust Co. acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 9,254 shares of the company’s stock, valued at approximately $2,114,000. AbbVie comprises about 1.4% of North Dallas Bank & Trust Co.’s investment portfolio, making the stock its 18th largest holding.

Several other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the period. Geode Capital Management LLC grew its stake in AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after acquiring an additional 4,190,487 shares during the period. Norges Bank purchased a new stake in AbbVie in the 4th quarter worth approximately $5,865,055,000. Capital Research Global Investors grew its stake in AbbVie by 0.7% in the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after acquiring an additional 177,370 shares during the period. Finally, Franklin Resources Inc. grew its stake in AbbVie by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock worth $3,400,274,000 after acquiring an additional 330,104 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie presented new data across its blood cancer portfolio at EHA 2026, with multiple oral presentations reinforcing progress in its oncology pipeline and long-term research efforts. AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
• Positive Sentiment: AbbVie has also been featured in “final trades” and “buy/hold” style commentary, suggesting traders remain constructive on the stock after its recent run and improved guidance outlook. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Neutral Sentiment: Investors are also watching articles that frame AbbVie as an undervalued dividend-growth name, which supports the bull case but does not bring new company-specific news. Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
• Negative Sentiment: AbbVie terminated its deal with I-Mab to develop a cancer drug, a setback that could be viewed as a pipeline/partnership disappointment even if the financial impact appears limited for now. AbbVie terminates deal with I-Mab to develop cancer drug

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Canaccord Genuity Group lifted their target price on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Barclays assumed coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price for the company. Piper Sandler lifted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Finally, Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Stock Up 1.0%

Shares of NYSE ABBV opened at $225.25 on Wednesday. AbbVie Inc. has a 52-week low of $181.73 and a 52-week high of $244.81. The firm has a fifty day moving average of $210.40 and a 200-day moving average of $219.12. The stock has a market capitalization of $397.97 billion, a PE ratio of 110.96, a P/E/G ratio of 0.68 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same period in the previous year, the company earned $2.46 EPS. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. Equities research analysts expect that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.